CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Clinical trial NCT06006390 · RECRUITING
Trial details
- NCT number
- NCT06006390
- Sponsor
- Chongqing Precision Biotech Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-07
- Primary completion
- 2025-12-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.